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ABSTRACT 
Aim: Activated hepatic stellate cells (HSC) play a critical role in liver fibrosis. 
Suppressing abnormal function of HSC or reversion from activated to quiescent form is 
a hopeful treatment for liver cirrhosis. The interaction between platelets and HSC 
remains unknown although platelets go through hepatic sinusoids surrounded by HSC. 
This study aimed at clarifying hypothesis that platelets control activation of HSC. 
Methods: We used human platelets, platelet extracts, and primary or immortalized 
human HSC. We examined the effect of platelets on the activation, DNA synthesis, type 
I collagen production, and fibrosis-relating gene expressions of HSC. We investigated 
what suppressed activation of HSC within platelets and examined the mechanism of 
controlling activation in vitro. 
Results: Platelets and platelet extracts suppressed activation of HSC. Platelets 
decreased type I collagen production without affecting DNA synthesis. Platelets 
increased the expression of matrix metallopeptidase 1. As platelet extracts co-cultured 
with an enzyme of degrading adenosine 5’-triphosphate (ATP) suppressed activation, 
we detected adenine nucleotides within platelets or on their surfaces and confirmed the 
degradation of adenine nucleotides by HSC and the production of adenosine. Adenosine 
and platelets increased the intracellular cyclic adenosine 5’-monophosphate (cAMP) 
which is important in quiescent HSC. Much amount of adenosine and ATP also 
suppressed activation of HSC. 
Conclusion: Activation of human HSC is suppressed by human platelets or 
platelet-derived ATP via adenosine-cAMP signaling pathway in vitro. Therefore, 
platelets have the possibility to be used in the treatment of liver cirrhosis. 
Key words: adenosine, ATP, cAMP, hepatic stellate cell, and liver fibrosis 
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INTRODUCTION 
Hepatic fibrosis is often observed under chronic liver damage induced by hepatitis 
viruses, alcohols, or obstructive jaundice.1 Since severe liver cirrhosis (LC) impairs 
liver function and can induce hepatocellular carcinoma, the reduction of fibrosis may 
eradicate them.2,3 Unfortunately, the clinical solution of established LC nowadays 
seems to be only liver transplantation.4 
 
Hepatic stellate cells (HSC) play a major role in hepatic fibrogenesis.5 A lot of 
experimental studies have focused on suppressing abnormal function of HSC, but they 
are not applied in clinical use.6-10 The characteristic features of activated HSC are the 
spindle-like shape, extensive extracellular matrix production, loss of cytoplasmic fat 
droplets, and active expression of alpha smooth muscle actin (α-SMA).1,11 The 
quiescent HSC indicates the opposite reactions, and the elevation of intracellular cyclic 
adenosine 5’-monophosphate (cAMP) has been reported to be an important factor in the 
anti-proliferative effect in HSC.12 A cyclic nucleotide phosphodiesterase inhibitor which 
increases the cytoplasmic cAMP concentration inhibits the transdifferentiation to the 
activated form of HSC.13 These previous reports suggest that the elevation of cAMP 
should be requisite to quiescent HSC. 
 
Platelets have critical roles in hemostasis, and at the same time also contain many kinds 
of substances which are not essential for hemostasis.14 The dense granules within 
platelets have low molecular materials, such as calcium, serotonin, adenosine 
5’-diphosphate (ADP), and adenosine 5’-triphosphate (ATP).15 They are stored in 
abundance and are released to close spaces.15,16 Platelets always go through hepatic 
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sinusoids and adhere there under certain conditions such as ischemia reperfusion injury 
or inflammation.17-19 Moreover, platelets can translocate into Disse’s space in mice,20 or 
can be directly adjacent to collagen fibrils in hepatitis C virus-induced fibrotic human 
liver.21 These reports suggest that platelets and HSC can be located closely in vivo, and 
that platelets can provide some substances into Disse’s space through multiple fenestrae 
on liver sinusoidal endothelial cell.22  
 
In LC patients, platelet counts are lower and ATP contents are less than those of healthy 
people.23,24 We have previously reported that thrombocytosis reduces liver fibrosis in 
rodent models.25,26 From these reports, we hypothesized that human platelets released 
their contents into the environment near HSC and suppressed activation of human HSC 
in normal liver. In this study, we examined the interaction between human HSC and 
human platelets and investigated their underlying mechanism to apply platelets to 
treatment for human LC. 
 
Methods 
Chemicals or Reagents  
ATP and apyrase, which degrades ATP, were purchased from Sigma-Aldrich Co. (St. 
Louis, MO). Adenosine, Dulbecco’s modified Eagle’s medium (D-MEM) and phosphate 
buffered saline (PBS) were purchased from Wako Pure Chemical Industries, Ltd. 
(Osaka, Japan). Acid citrate dextrose formula A is the anticoagulant product used in this 
study and was purchased from TERUMO Co. (Tokyo, Japan). Anti-human vascular 
endothelial growth factor (VEGF) antibody MAB293 was purchased from R&D 
Systems, Inc. (Minneapolis, MN). Anti-human insulin-like growth factor -1 receptor 
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(IGF-1R) inhibitor II and platelet-derived growth factor-receptor (PDGF-R) tyrosine 
kinase inhibitor IV were purchased from Calbiochem, Inc. (San Diego, CA). All 
chemicals are commercially available. 
 
Cell culture 
TWNT-1, which is the immortalized human HSC cell line and is kindly donated from Dr. 
Kobayashi, Okayama University, and primary human HSC were cultured in D-MEM 
supplemented with 10% fetal bovine serum.27 Cell culture chambers (Becton Dickinson 
Labware, Franklin Lakes, NJ) whose pore sizes are 0.2 μm were used to separate 
platelets from TWNT-1. Primary human HSCs were obtained from surgical specimens 
by a two-step collagenase perfusion method, followed by density gradient 
centrifugation.28,29 Surgical specimens were collected under written informed consent 
and approval by the Ethics Committee and the institutional review board of University 
of Tsukuba hospital. All cultures were maintained at 37°C in a humidified atmosphere 
containing 5% CO2.   
 
Platelet preparation  
Blood was obtained from healthy volunteers using an anticoagulant after obtaining 
informed consents, as previously reported.30 Washed platelets were suspended in PBS 
and used as platelet group (PLT). To obtain platelet extracts, platelets were disrupted by 
freezing and thawing for five cycles and centrifuged at 15000 g, 4°C for 30 min. The 
supernatant was used as platelet extracts. 
 
Light microscopy 
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To examine morphologic changes of TWNT-1 after adding platelets, cultured cells were 
photographed using light microscopy IX71 (OLYMPUS Corp., Tokyo) and the digital 
camera DP71 (OLYMPUS Corp.) under the high magnification power (x 200) after 
washing dishes with PBS and removing apoptotic cells or platelets. We divided cells 
into two groups according their shapes and counted the number of cells. One group 
consisted of the spindle shaped cells that have a long axis more than twice that of the 
short axis. The other consisted of the oval shaped cells that have a long axis less than 
twice that of the short axis. The spindle one was considered as highly-activated status 
and the oval one was considered as resting status in this study.11 
 
Western blot  
Cultured cells were washed with PBS, lysated, subjected to 10% SDS-PAGE, and 
transferred to a nitrocellulose membrane (Millipore Co., Billerica, MA). Primary 
antibodies were mouse monoclonal anti-human smooth muscle actin (DAKO Co., 
Grostrup, Denmark) and rabbit polyclonal anti-G3PDH antibody (TREVIGEN, Inc., 
Gaithersburg, MD). Secondary antibodies were anti-mouse or anti-rabbit IgG 
HRP-linked antibody (Cell Signaling Technology, Inc., Danvers, MA). All antibodies 
were diluted to 1:1000 except for anti-G3PDH (1:5000). Because α-SMA is a 
well-known marker of HSC activation,2 we used the anti-human smooth muscle actin 
antibody. GAPDH was used as the endogenous control. 
 
DNA synthesis assay 
The effect of platelets on DNA synthesis was measured using Cell Proliferation ELISA, 
5-bromo-2’-deoxyuridine (BrdU) colorimetric kit (Roche Ltd.). TWNT-1 (5x103 cells) 
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were plated into each well of 96-well dishes. Platelets were added and cultured for 24 
hours. The plate was washed before adding BrdU. 
 
RNA extraction and reverse transcription – polymerase chain reaction (RT-PCR) 
RNA extraction was carried out using FastPure RNA Kit (Takara BIO Inc., Otsu, Japan), 
following the procedure recommended by the manufacturer. The synthesis of 
complimentary DNA was performed using AMV Reverse Transcriptase (Promega Corp., 
Madison, WI) and random primer (Takara BIO, Inc.). Briefly, the mixture of 1 mM 
dNTPs (Fermentas LIFE SCIENCES Corp., Ontario, Canada), 0.025 μg/μl random 
primer, 0.25 U/μl reverse transcriptase, and 500 ng total RNA were incubated at 30°C 
for 10 min, 37°C for 60 min, 95°C for 5 min, and 4°C before storage in -80°C. 
 
Quantitative real-time PCR 
Primers for real-time PCR were designed by Primer Express Software for Real-Time 
PCR version 3.0 (Applied Biosystems Corp., Foster, CA) using GenBank sequences. 
Primers were purchased from Hokkaido System Science Co., Ltd. (Hokkaido, Japan) 
and listed in Table 1. We examined ACTA2, COL1A1, MMP-1, TIMP-1, ADORA1, 
ADORA2A, ADORA2B, ADORA3 and GAPDH (encoding alpha 2 helix of α-SMA, 
pro-alpha 1 chain of type I collagen, matrix metallopeptidase-1, tissue inhibitor of 
metalloproteinases 1, adenosine A1 receptor, adenosine A2A receptor, adenosine A2B 
receptor, adenosine A3 receptor, and glyceraldehyde-3-phosphate dehydrogenase, 
respectively). The real-time PCR was performed using SYBR Green Realtime PCR 
Master Mix-Plus (TOYOBO Co., Ltd., Osaka, Japan) and Applied Biosystems 7300 
Real-time PCR system (Applied Biosystems Corp.), following the procedure 
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recommended by the manufacturer. GAPDH was used as the endogenous control. 
 
Agarose gel-electrophoresis 
PCR products were subjected to 1% agarose gel containing 0.005% ethidium bromide 
(Wako Pure Chemical Industries, Ltd.). After the electrophoresis was performed, the gel 
was pictured when ultraviolet was radiated using Electronic U.V. Transilluminator, 
FAS-III (TOYOBO Co., Ltd.). 
 
Assay of type I collagen in the cultured medium of TWNT-1  
The amount of type I collagen was measured using anti-human procollagen type I 
C-peptide ELISA kit (Takara BIO, Inc.). The supernatant of cultured medium was 
separated, centrifuged at 15000 g, 4°C for 30 min to remove the debris, and stored at 
-80°C until analysis.  
 
Analysis of adenine nucleotide concentration  
The concentrations of ATP, ADP, and AMP in platelets were measured by high 
performance liquid chromatography (HPLC) as previously reported.31 The HPLC 
system for adenosine measurement was the GULLIVER HPLC-900 (JASCO Corp., 
Tokyo, Japan). The column was Wakosil-II 5C18HG (Wako Pure Chemical Industries, 
Ltd.) and ultraviolet absorbance was measured at 260 nm. The running buffer was 60 
mM ammonium phosphate buffer which was adjusted to pH 5.0. In addition, we used 
Adenosine 5’-triphosphate Bioluminescent Assay kit (Sigma-Aldrich Co.) to assess the 
ATP concentration on the platelet’s surface, referring to the procedure of measuring 
cellular surface concentration of ATP.32 Briefly, washed platelets were centrifuged at 
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1000 g, 4°C for 5 min. The pellet was loosened using a large pipette. After the aliquot of 
10 μl pellet and the same amount of Assay Mix in the kit were mixed, the chemical 
luminescence was measured by luminometer, TD 20 / 20 (Promega Corp.). The same 
volume of ATP solution was used as control.  
 
Measurement of intracellular cAMP  
As cAMP is the second messenger of adenosine signaling pathway, we examined 
cytoplasmic cAMP of TWNT-1.33 TWNT-1 (7x103 cells) were plated into each well of 
96-well dishes and cultured over night. We added stimulants, incubated them for an 
hour, and washed the plate with PBS before starting measurements. The intracellular 
cAMP was investigated using cAMP-Screen Assay kit (Applied Biosystems Corp.), 
following the procedure recommended by the manufacturer. 
 
Statistical Analysis  
Data are expressed as means ± standard deviation. Student t test was performed to 
assess statistical significance. P values less than 0.05 were considered statistically 
significant. 
 
RESULTS 
Human platelets suppress the expression of α-SMA 
The expression of α-SMA was measured by Western blot analysis at 1, 4, or 7 days after 
incubating platelets with TWNT-1. While α-SMA expression was increased with or 
without platelets, platelets reduced their increment (Fig. 1a). We also examined α-SMA 
expression after adding platelets to cell culture inserts. It was not suppressed (Fig. 1b). 
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These findings indicate that human platelets suppress activation of TWNT-1, and that 
platelets can exhibit it more efficiently when being located close to TWNT-1. 
 
Platelets suppress cellular extension of TWNT-1 
TWNT-1 co-cultured with platelets were photographed at random on day 1, 4, and 7, 
and separated into two groups in terms of their shapes. More oval type cells were shown 
in the PLT group than the control group. The representative pictures are shown on day 4 
(Fig. 1c). The ratio of oval type cells in total decreased in a time-dependent manner in 
both groups. However, the PLT group showed a significant large ratio on day 4 and 7 
(Fig. 1d). This result indicates that platelets also have some effects on keeping TWNT-1 
quiescent in terms of their shapes. 
 
Platelets do not affect DNA synthesis of TWNT-1 
The BrdU uptake was not changed when incubating platelets with TWNT-1 (Fig. 1e).  
 
Platelets decrease the production of type I collagen 
The concentration of type I collagen in cultured medium was significantly decreased in 
the PLT group on day 4 (Fig. 1f).  
 
Platelets have influences on fibrosis-relating gene expressions 
Total RNAs were extracted after incubating platelets with TWNT-1 for 24 hours. After 
performing real-time PCR, each group was compared with the control group. ACTA2 
and COL1A1 were significantly decreased in the PLT group (Fig. 2a, b, respectively). 
MMP-1 and TIMP-1 were significantly increased in the PLT group (Fig. 2c, d, 
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respectively). These findings demonstrate that platelets suppress HSC activation and 
affect the amount of intrahepatic extracellular matrix. Since TWNT-1 express more 
α-SMA in a time-dependent manner (Fig. 1a), we cultured TWNT-1 for 1, 4, or 7 days 
to prepare activated TWNT-1, incubated platelets with them for another 24 hours, and 
extracted total RNAs to investigate changes of ACTA2 in the activated TWNT-1. On 
day 2, 5, and 8, all PLT groups suppressed ACTA2 expression (Fig. 2e). This result 
means that platelets suppress activation of TWNT-1 which has been activated to some 
degree. 
 
Platelet extracts suppress ACTA2 expression more efficiently when incubated with 
apyrase 
To examine what contributes to suppression of ACTA2 expression, we incubated four 
kinds of reagents before adding platelet extracts as follows: PDGF-R inhibitor, 
anti-VEGF antibody, IGF-1R inhibitor, and apyrase which degrades ATP to ADP or 
AMP. Platelet extracts also suppressed ACTA2 expression as well as platelets (Fig. 3a). 
PDGF-R inhibitor, anti-VEGF antibody, and IGF-1R inhibitor had no effect on ACTA2 
expression (Fig. 3b, c, d, respectively). On the other hand, apyrase reduced ACTA2 
expression in a dose-dependent manner (Fig. 3e). This result implies that ATP 
derivatives made by apyrase have more influence on ACTA2 expression than ATP in 
platelet extracts. 
 
Platelets contain and release large amounts of ATP 
We studied adenine nucleotide concentrations both in platelets by HPLC and on 
platelet’s surfaces by luciferase-mediated chemical luminescence to explain the effect of 
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derivatives made by apyrase. Platelets contained ATP, ADP, and AMP (Fig. 4a). The 
number of chemical luminescent counts at platelet’s surfaces without ATP 
administration was significantly higher than that of 100 μM ATP solution (Fig. 4b). 
These results demonstrate that platelets contain large amounts of ATP inside or near 
their surfaces in vitro. 
 
HSC degrades ATP and produces adenosine in vitro 
After culturing TWNT-1 or primary HSC with ATP, we studied the total value of ATP, 
ADP, and AMP in the cultured medium by HPLC. The values of both the TWNT-1 
group and the primary HSC group were significantly decreased in 6 and 24 hours after 
incubation, compared to control which did not contain any cells (Fig. 4c). After 
culturing TWNT-1 with ATP or adenosine for 24 hours, we investigated adenosine 
concentrations in the cultured medium by HPLC as well. The adenosine concentrations 
after incubating with adenosine or ATP for 24 hours were significantly increased 
comparing to TWNT-1 alone (Fig. 4d). The adenosine concentration in ATP alone was 
extremely low (figure not shown). These results suggest that TWNT-1 metabolizes 
adenosine phosphates and produces adenosine in the medium. 
 
Adenosine and platelets increase cytoplasmic cAMP in TWNT-1 
As TWNT-1 produced adenosine in vitro (Fig. 4d), we examined expression of 
adenosine receptors and changes of their intracellular signaling molecule, i.e., cAMP 
after incubating adenosine or platelets with TWNT-1. We confirmed four types of 
mRNA of adenosine receptors by agarose gel-electrophoresis (Fig. 4e). The cytoplasmic 
cAMP was significantly increased when incubating 1000 μM adenosine and platelets 
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(Fig. 4f). These results suggest that platelets and large amounts of adenosine activate 
adenosine-cAMP signaling pathway in TWNT-1.  
 
Adenosine and ATP suppress HSC activation 
After incubating adenosine with TWNT-1, α-SMA expression was examined by Western 
blot. It was suppressed after incubating 1 mM adenosine with TWNT-1 during 1, 4, and 
7 days (Fig. 5a). The α-SMA expression in primary human HSC was studied as well. It 
was also suppressed when incubating with 1 mM adenosine, 1 mM ATP, and platelets 
(Fig. 5b). DNA synthesis was not changed after incubating ATP with TWNT-1 for 24 
hours (Fig. 5c). These results indicate that a large amount of ATP or adenosine 
suppresses HSC activation without affecting DNA synthesis. 
 
DISCUSSION 
Activated HSC produces a lot of extracellular matrix and contributes to deteriorate 
hepatic fibrogenesis.1,2 Since we have already found that hepatic fibrosis decreases after 
inducing thrombocytosis in rodents,25,26 we hypothesized that human platelets would 
also have an anti-fibrotic effect. In this study, we indicated that human platelets 
suppress HSC activation and collagen production in human HSC via an 
adenosine-cAMP signaling pathway in vitro.  
 
It is likely that HSC is physiologically exposed to high concentration of ATP or its 
derivatives in the microcirculation because ATP is released from red blood cells or 
intrahepatic cells and hepatocytes are abundant in ATP.34-36 On the other hand, adenine 
nucleotides decrease very rapidly in circulating blood through the degradation by 
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functional enzymes or the uptake from erythrocytes.37 It seems to be difficult to 
examine the exact concentration of adenine nucleotides without degradation in vivo. 
This is the limitation of this study. 
 
The DNA synthesis was not changed after incubating platelets or ATP with TWNT-1. 
These results may indicate that the volume of ATP or platelets in this study is not 
sufficient to stimulate HSC proliferation in vitro. 
 
We clearly indicated that HSC produces adenosine by degrading adenine nucleotides. 
The nucleotide-hydrolysing pathway mainly comprises four enzymes, ecto-nucleotide 
triphosphate diphosphohydrolase family (E-NTPDase), ecto-nucleotide 
pyrophosphatase/phosphodiesterase family (E-NPP), ecto-5’-nucleotidase (CD73), and 
alkaline phosphatase. HSC has been also reported to show these activities,38-40 which 
demonstrates that the extracellular ATP may be easily broken down to adenosine by 
HSC in vivo. Andrade et al. implied that CD73-dependent adenosine generation might 
regulate the function of quiescent HSC.40 Hernández-Muñoz R et al. reported that 
adenosine administration blocks active hepatic fibrogenesis and increases the collagen 
degradation in rats.41,42 These reports together with our results imply that adenosine 
seems to be important in quiescent HSC and anti-fibrotic effects. 
 
The signal from adenosine is transmitted by four types of adenosine receptors; A1R, 
A2AR, A2BR, and A3R.33 They are all G protein-coupled receptors whose effectors are 
adenylyl cyclase (AC) which produces cAMP. We demonstrated the elevation of cAMP 
in TWNT-1 because it activates cAMP-dependent protein kinase (PKA) and leads to 
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phosphorylation of cAMP-response element binding protein (CREB) on Ser133.43 
Houglum et al. reported that phosphorylation of CREB on Ser133 might be 
indispensable for quiescent HSC.44 From these reports and results of this study, we 
hypothesize the mechanism of suppressing HSC activation by platelets via 
adenosine-cAMP signaling pathway in vitro (Fig. 6).  
 
In conclusion, human platelets contribute to suppression of both HSC activation and 
type I collagen production in vitro. This is mediated by adenosine-cAMP signaling 
pathway in HSC. We suggest that the effective transport of a high amount of adenine 
nucleotide into Disse’s space should be a key process in the treatment for human LC.  
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FIGURE LEGENDS 
Figure 1 Platelets suppress activation of hepatic stellate cells (HSC) and collagen 
production. 
The immortalized human HSC, TWNT-1 (1x104 cells), were plated on 6-well dishes 
and incubated with platelets (1x108 cells) for 1, 4, and 7 days. (a) The expression of 
alpha smooth muscle actin (α-SMA) which is a well-known marker of HSC activation 
was examined by Western blot (first row, α-SMA; second row, GAPDH; third row, 
α-SMA in platelets themselves). (b) After incubating platelets with TWNT-1 separately 
using chambers, α-SMA expression was examined as well. (c) TWNT-1 incubated with 
PBS (control) or platelets (PLT) for 1, 4 and 7 days were photographed and separated 
into two groups (n = 10). We determined that the oval shaped cell had a long axis less 
than twice that of the short axis and was not as activated as the spindle one.11 The 
representative figures at day 4 are shown (arrow; oval shaped cell). (d) The ratios of 
oval shaped cells in total were counted at day 1, 4, and 7. (e) DNA synthesis in 
TWNT-1 was examined by 5-bromo-2’-deoxyuridine (BrdU) uptake assay after 
incubating platelets (PLT) for 24 hours (n = 8). (f) The supernatant of co-cultured 
medium with platelets for 1 or 4 days was examined by ELISA for type I collagen (n = 
6). All results are representative of three independent experiments (mean ± SD). * P < 
0.01.  
 
Figure 2 Platelets affect fibrosis-relating gene expressions. 
TWNT-1 (1x106 cells) were plated on 6 cm dishes and incubated with PBS (control) 
and platelets (2x108 cells, PLT) for 24 hours. Total RNAs were extracted and real-time 
PCR was performed (n = 3). (a-d) ACTA2, COL1A1, MMP-1, and TIMP-1 were 
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examined, respectively. (e) In ACTA2, after TWNT-1 (1x 106, 5x105, and 1x105 cells) 
were cultured for 1, 4, and 7 days to obtain subconfluent dishes at the same time, 
respectively, TWNT-1 were incubated with platelets for another 24 hours and real-time 
PCR was performed as well. All results are representative of three independent 
experiments (mean ± SD). * P < 0.01, ** P < 0.05 versus control. ACTA2, alpha 2 helix 
of α-SMA; COL1A1, pro-alpha 1 chain of type I collagen; MMP-1, matrix 
metallopeptidase-1; TIMP-1, tissue inhibitor of metalloproteinases-1; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase.  
 
Figure 3 Platelet extracts suppress ACTA2 expression more efficiently when incubated 
with apyrase. 
(a) TWNT-1 (1x106 cells) were plated on 6 cm dishes and incubated with PBS (control) 
and platelet extracts (equivalent to 2x108 cells) for 24 hours. Total RNAs were extracted 
and real-time PCR for ACTA2 was performed (n = 3,* P < 0.01 versus control). (b-e) 
TWNT-1 (1x106 cells) were incubated with platelet-derived growth factor receptor 
(PDGF-R) inhibitor, anti-vascular endothelial growth factor (VEGF) antibody, 
insulin-like growth factor-1 receptor (IGF-1R) inhibitor, or apyrase which degrades 
adenosine 5’-triphosphate (ATP) for 30 minutes, respectively. Then, platelet extracts 
(equivalent to 2x108 cells) were incubated for 24 hours. Real-time PCR for ACTA2 was 
performed as well (n = 3, * P < 0.01, ** P < 0.05 versus 0 U / ml). All results are 
representative of three independent experiments (mean ± SD).  
 
Figure 4 HSC dephosphorylates platelet-derived ATP and produces adenosine which 
activates adenosine-cyclic adenosine 5’-monophosphate (cAMP) signaling pathway. 
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(a) Adenine nucleotide concentrations of platelets were measured by high performance 
liquid chromatography (HPLC) (n = 5). (b) The ATP concentration of platelet’s surfaces 
was examined by luciferase reaction (n = 5, *P < 0.01 versus 100 μM). (c) After 
TWNT-1 or primary human HSC (3x104 cells) were incubated with 1 mM ATP, the 
total amount of ATP, adenosine 5’-diphosphate (ADP), and AMP in the medium was 
measured at 0, 6, and 24 hours by HPLC (n = 5, * P < 0.01). (d) After culturing 
TWNT-1 with 1 mM adenosine or 1 mM ATP for 24 hours, the adenosine concentration 
in the medium was investigated by HPLC (n = 5, * P < 0.01). (e) After PCR for four 
types of adenosine receptors in TWNT-1, we examined their expressions by agarose 
gel-electrophoresis. (f) TWNT-1 (7x103 cells) were plated on 96-well dishes and 
incubated with adenosine or platelets (1x107 cells) for an hour. After washing, the 
intracellular cAMP was measured (n = 8, ** P < 0.05 versus 0 μM). All results are 
representative of three independent experiments (mean ± SD). A1-R, adenosine A1 
receptor; A2A-R, adenosine A2A receptor; A2B-R, adenosine A2B receptor; A3-R, 
adenosine A3 receptor. 
 
Figure 5 Much amount of adenine nucleotides suppresses activation of HSC. 
(a) TWNT-1 (1x104 cells) were plated on 6-well dishes and incubated with adenosine 
for 1, 4, and 7 days. The α-SMA expression was examined by Western blot. (b) Primary 
human HSC (5x103 cells) were plated and incubated with PBS (control), platelets 
(1x108 cells, PLT), 1 mM ATP, or 1 mM adenosine during 1, 4, and 7 days. The α-SMA 
expression was investigated as well. (c) After incubating TWNT-1 (5x103 cells) with 
ATP for 24 hours, the BrdU uptake was measured (n = 8). All results are representative 
of three independent experiments (mean ± SD).  
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Figure 6 Scheme for inactivation of human HSC by human platelets. Platelets contact 
with HSC. Platelets release adenine nucleotides into a close environment. They are 
hydrolyzed by ecto-nucleotide triphosphate diphosphohydrolase (E-NTPDase), 
ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP), or ecto-5’-nucleotidase 
(CD73) on HSC plasma membrane, which produces large amounts of adenosine around 
HSC. Adenosine receptors transmit signals into cytoplasm by activating adenylyl 
cyclase (AC). AC increases intracellular cAMP. The elevation of cAMP activates 
cAMP-dependent protein kinase (PKA). The cAMP-response element binding protein 
(CREB) is phosphorylated by PKA. This phosphorylation is an important factor in 
quiescent HSC that expresses less α-SMA and produces less extracellular matrix. 
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Table 1  
The list of primers used in PCR 
Gene name GenBank 
accession number 
forward (5’ to 3’) reverse (5’ to 3’) 
ACTA2 NM_001613  CAGGGCTGTTTTCCCATCCA CCTCTTTTGCTCTGTGCTTCGT 
COL1A1 Z74615 GGGCTTGCCTTCCATTCCT GGAAGTAGAAAGGTTTGCGGTATAA 
MMP1 NM_002421  CACAGCTTCCCAGCGACTCT GCCACTATTTCTCCGCTTTTCA 
TIMP1 NM_003254 ACTGTTGGCTGTGAGGAATGC GGTCCGTCCACAAGCAATG 
ADORA1 NM_000674 CCTCACGCACGGCAACTC TGGCAGCGGAAATGGTCAT 
ADORA2A NM_000675 CTGCTGGCTGCCCCTACAC GAAGGGATTCACAACCGAATTG 
ADORA2B M97759 GCTCTTCGCCATCCCCTTT CACGAAGCAGGCGAGGAA 
ADORA3 NM_000677 GTCAGCCTGGGCATCACAAT CACAGCGATGGCCAGCAA 
GAPDH NM_002046 GGAGTCCACTGGCGTCTTCA TTCACACCCATGACGAACATG 
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